Company profile
Home - Purespring Therapeutics
Purespring Therapeutics Limited is a UK company with status active founded in 2020 based in London.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
SH10 | Transaction MzUyMDI2MDc5M2FkaXF6a2N4 | Paper/PDF filed
Published 27 May 2026 23:11
SH08 | Transaction MzUyMDI2MDc5MWFkaXF6a2N4 | Paper/PDF filed
Published 27 May 2026 22:56
PSC05 | Transaction MzUxNjY5MzYyNmFkaXF6a2N4
Published 16 Apr 2026 15:45
PSC05 | Transaction MzUxNjY5MTgyMmFkaXF6a2N4
Published 16 Apr 2026 15:33
Last confirmation statement made up date
Last accounts made up date
RESOLUTIONS | Transaction WURFQzhBSDVhZGlxemtjeA | Paper/PDF filed
Published 31 Oct 2024 07:52
SH01 | Transaction MzQ0MTEwMzA5M2FkaXF6a2N4
Published 29 Oct 2024 11:17
AP01 | Transaction MzQ0MTEwMTczMmFkaXF6a2N4
Published 29 Oct 2024 11:12
SH01 | Transaction MzQ0MTEwMjM0N2FkaXF6a2N4
Published 28 Oct 2024 11:32
TM01 | Transaction MzQ0MTEwMTcxNGFkaXF6a2N4
Published 28 Oct 2024 11:28
AP01 | Transaction MzQ0MTEwMTcyOWFkaXF6a2N4
Published 28 Oct 2024 11:28
AP01 | Transaction MzQ0MTEwMTcyN2FkaXF6a2N4
Published 28 Oct 2024 11:28
TM01 | Transaction MzQ0MTEwMTcxOWFkaXF6a2N4
Published 28 Oct 2024 11:28
TM01 | Transaction MzQ0MTEwMTcwNmFkaXF6a2N4
Published 28 Oct 2024 11:28
SH08 | Transaction MzQ0MDYzNDIxNmFkaXF6a2N4 | Paper/PDF filed
Published 26 Oct 2024 06:24
SH10 | Transaction MzQ0MDYzNDI5NmFkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 07:11
RESOLUTIONS | Transaction WUQ5MTZDVkZhZGlxemtjeA | Paper/PDF filed
Published 14 Aug 2024 07:55
Company registered at Companies House
Purespring Therapeutics develops gene therapies for kidney related diseases.
Purespring will develop gene therapies directly targeting the glomerulus in the kidney, which could see treatment progress from lab to patients in three or four years. The company will also have access to an in-vivo functional screening platform, FunSel, to screen for cell-specific protective factors delivered via gene therapy, that could have applications across several kidney diseases.
6 patents filed
The University of Bristol has secured a £45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company.
